



## Immune Response against SARS-CoV-2

Guest Editor:

**Dr. Angela Stufano**

DIM Section of Occupational  
Medicine "EC Vigliani", Università  
degli studi di Bari Aldo Moro,  
70121 Bari, Italy

Deadline for manuscript  
submissions:

**closed (31 January 2023)**

### Message from the Guest Editor

Dear Colleagues,

This special issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the immune response in individuals infected or vaccinated against SARS-CoV-2. Both basic and applied research papers that aim to improve the understanding of the immune response against SARS-CoV-2, short- and long-term effects of host immune responses to SARS-CoV-2, improved diagnostic methods, vaccination-related immune response, and intervention strategies for the prevention and management of COVID-19-related autoimmune reactions are welcome.

We cordially invite you to contribute to this special issue to advance our knowledge of SARS-CoV-2 and to discover together the means to overcome the pandemic.

I look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)